[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligoprogressive-nodal-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligoprogressive-nodal-metastases":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":38,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100371352",false,"NCT04115254","Stereotactic Magnetic Resonance Guided Radiation Therapy","A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)","Inclusion Criteria:\n\n* Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.\n* Tumor size ≤ 7cm\n* Age 18 years of older.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Specific eligibility requirements for each disease site with be covered in each specific cohort.\n\nExclusion Criteria:\n\n* Specific exclusion requirements for each disease site with be covered in each specific cohort\n* History of allergic reactions attributed to gadolinium-based IV contrast.\n\n  \\-- Note: If a patient will not receive contrast, this is not applicable\n* Pregnant women are excluded from this study.\n* Severe claustrophobia or anxiety\n* Participants who cannot undergo an MRI","ALL","18 Years",{"count":18,"type":19},397,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.\n\n* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.\n* Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures",[25,26,27,28,29,30,31,32,33,34,35,36,37],"Pancreas Cancer","Lung Cancer","Renal Cancer","Adrenal Metastases","Prostate Cancer","Liver Metastases","Oligoprogressive Nodal Metastases","Metachronous Nodal Metastases","Synchronous Nodal Metastases","Mesothelioma","Spine Metastases","Brain Metastases","Borderline Resectable Pancreatic Carcinoma",[39,40,25,26,27,28,29,30,41,42,43,44,45,46],"Magnetic Resonance Imaging (MRI)","MRIdian Linear Accelerator","Oligoprogressive","Metachronous","Synchronous","Spine","Prostate Boost","Pelvic Re Irradiation","RECRUITING","2025-11-11",{"date":50,"type":51},"2025-11-13","ACTUAL",{"date":53,"type":51},"2019-10-22",{"date":55,"type":19},"2028-06",{"name":57,"class":58},"Dana-Farber Cancer Institute","OTHER",2,""]